Major Changes in the Treatment of Osteoporosis, Rheumatoid Arthritis, andRelated Diseases Lie Ahead, According to a Decision Resources Report
WALTHAM, Mass., Dec 18 /PRNewswire/ -- The Outlook for Bone and Connective Tissue Disease Therapy Markets, a new DR Report from Decision Resources, is a timely study that discusses new approaches to treating a broad range of bone and connective tissue diseases, and their potential impact on sales in their relevant therapeutic group.
We predict the following developments:
-- Direct sales of drugs to treat bone and connective tissue diseases will
reach $25 billion annually by 2007.
-- Improved COX-2-specific NSAIDs such as celebrex (celecoxib) from Searle
and rofecoxib (vioxx) from Merck will likely be launched in 1999 and
2000, respectively. These NSAIDs are designed to relieve pain and
inflammation in autoimmune diseases and osteoarthritis with reduced GI
side effects. In 2001 we will see the launch of NSAIDs with a more
potent analgesic effect -- eltanac from Byk Gulden and tinoprofen from
Japan Tobacco.
-- An increasing commitment to identify genomic aberrations and translate
the findings into new approaches for diagnosis and therapy.
-- Commercial development of TNF antagonists for severe rheumatoid
arthritis will continue to be focused on drugs such as Immunex's Enbrel
(etanercept) that antagonize the action of the cytokines rather than
chemokines.
-- We expect a steady convergence of therapies that are used for a variety
of autoimmune diseases and which have the same basic origin of immune
system dysfunction. As the convergence plays out, certain drugs found
to be multi-indicational will see dramatic sales growth potential.
This hypothesis is well illustrated in the case of Arava (Hoechst
Marion Roussel), recently approved for rheumatoid arthritis and now in
clinical trials for lupus.
-- The use of immunosuppressive drugs (predominantly methotrexate and
cyclophosphamide) for control over the progression of autoimmune
disease will increase significantly during the next decade.
Journalists, contact: Cindy Corona, phone 781-487-3721, e-mail corona@dresources.com.
Sales inquiries, contact: Jean Carbone, phone 781-487-3737, e-mail drreports@dresources.com. This report is available for $3200.00.
DR Reports analyze technological advances, regulatory developments, and business trends in the health care industry. Decision Resources was founded as a subsidiary of Arthur D. Little, Inc., and is now an independent, employee-owned health care research and consulting firm.
SOURCE Decision Resources
CO: Decision Resources
ST: Massachusetts
IN: MTC
SU:
12/18/98 09:47 EST prnewswire.com
|
